Malignant melanoma and HIV infection - Aggressive course despite immune reconstitution

Onkologie

Volumn 28, Issue 1, 2005, Pages

  Hoffmann, Christian ^a   Horst, Heinz August ^a   Weichenthal, Michael ^a   Hauschild, Axel ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

AIDS; HAART; HIV; Malignant melanoma

Indexed keywords

ALPHA2B INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; HISTAMINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; RECOMBINANT INTERLEUKIN 2; STAVUDINE;

ADULT; ARTICLE; CANCER GROWTH; CANCER MORTALITY; CASE REPORT; CELL COUNT; CELLULAR IMMUNITY; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; HUMORAL IMMUNITY; LIVER METASTASIS; LYMPHOCYTE SUBPOPULATION; MALE; MELANOMA; SPLEEN;

EID: 12544253705     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000082291     Document Type: Article

References (24)

1. Mocroft A, Vella S, Benfield TL, Chiesi A, Miller V, Gargalianos P, d'Arminio Monforte A, Yust I, Bruun JN, Phillips AN, Lundgren JD: Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998;352:1725-1730.
2. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
3. Hoffmann C, Wolf E, Fätkenheuer G, Buhk T, Stoehr A, Plettenberg A, Stellbrink HJ, Jäger H, Siebert U, Horst HA: Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS 2003;17:1521-1529.
4. Cattelan AM, Trevenzoli M, Aversa SM: Recent advances in the treatment of AIDS-related Kaposi's sarcoma. Am J Clin Dermatol 2002;3:451-462.
5. Müller C, Pehamberger H, Binder M, Zielinski CC: Defective interferon-augmented natural killer cell activity in patients with metastatic malignant melanoma. J Cancer Res Clin Oncol 1989;115:393-396.
6. Hemminki K, Jiang Y, Steineck G: Skin cancer and non-Hodgkin's lymphoma as second malignancies. Markers of impaired immune function? Eur J Cancer 2003;39:223-239.
7. Mackensen A, Carcelain G, Viel S, Raynal MC, Michalaki H, Triebel F, Bosq J, Hercend T: Direct evidence to support the immunosurveillance concept in a human regressive melanoma. J Clin Invest 1994,93:1397-1402.
8. Mihm MC Jr., Clemente CG, Cascinelli N: Tumor infiltrating lymphocytes in lymph node melanoma metastases: A histopathologic prognostic indicator and an expression of local immune response. Lab Invest 1996;74:43-47.
9. Hsueh EC, Gupta RK, Qi K, Morton DL: Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998;16:2913-2920.
10. Rasokat H, Steigleder GK, Bendick C, Muller S, Meller M: Malignant melanoma and HIV infection. Z Hautkr 1989;64:581-582, 587.
11. Tindall B, Finlayson R, Mutimer K, Billson FA, Munro VF, Cooper DA: Malignant melanoma associated with human immunodeficiency virus infection in three homosexual men. J Am Acad Dermatol 1989;20:587-591.
12. Grulich AE, Li Y, McDonald A, Correll PK, Law MG, Kaldor JM: Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002;16:1155-1161.
13. Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA: Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr 2003;32:527-533.
14. Frisch M, Biggar RJ, Engels EA, Goedert JJ, AIDS-Cancer Match Registry Study Group: Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285:1736-1745.
15. Retsas S, Quigley M, Pectasides D, Macrae K, Henry K: Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer 1994;73:2119-2130.
16. McGregor JM, Newell M, Ross J, Kirkham N, McGibbon DH, Darley C: Cutaneous malignant melanoma and human immunodeficiency virus (HIV) infection: A report of three cases. Br J Dermatol 1992;126:516-519.
17. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr., Walker RE, Plis MA, Spooner K, Metcalf JA, Baseler M, Fyfe G, Lane HC: Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1997;336:1260-1261.
18. Atkins MB, Kunkel L, Sznol M, Rosenberg SA: High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J Sci Am 2000;Suppl 1:S11-S14.
19. Calista D: Five cases of melanoma in HIV positive patients. Eur J Dermatol 2001;11:446-449.
20. Rodrigues LK, Klencke BJ, Vin-Christian K, Berger TG, Crawford RI, Miller JR 3rd, Ferreira CM, Nosrati M, Kashani-Sabet M: Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 2002;138:765-770.
21. Kind GM, VonRoenn J, Jansen DA, Bailey MH, Lewis VL Jr.: Human immunodeficiency virus infection and subsequent melanoma. Ann Plast Surg 1996;37:273-277.
22. Aboulafia DM: Malignant melanoma in an HIV-infected man: A case report and literature review. Cancer Invest 1998;16:217-224.
23. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, Palladino C, Leone P, Bugarini R, Malavasi L, Cafaro A, Falchi M, Valdembri D, Rezza G, Bussolino F, Monini P, Ensoli B: HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002;8:225-232.
24. Streit M, Detmar M: Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003;22:3172-3179.